Mamiai and Yitaning Boast their Brand Excellence in 2023 CHEO

In 2023, the 16th CHEO(China Health Ecology Organization) was successfully held in Boao, Hainan from August 9th to 14th, with the theme of “Reshape the Industry with Dual Synergy, Open a New Era of Individual Health.”

In 2023, the 16th CHEO(China Health Ecology Organization) was successfully held in Boao, Hainan from August 9th to 14th, with the theme of “Reshape the Industry with Dual Synergy, Open a New Era of Individual Health.”

The symposium attracted over 8,000 industry experts from diverse sectors, including government agencies, domestic and foreign mainstream brand industries, commercial & retail companies, novel drug companies, biotechnology firms, CXO leadership, digital technology innovators, medical and health service institutions, domestic and foreign capital powerhouses, commercial insurance institutions, prominent media outlets. They discussed how to fulfill the interaction of ecological value with new developmental pathways. Additionally, the 2023 Health Industry Brand List was grandly announced.


Drawing upon data from Sinohealth, brands were meticulously evaluated according to four critical dimensions: product value, profit expectations, market value, and user praise. Mamiai and Yitaning, products were once again nominated on the 2023 Brand List and won the Gold Award. This recognition serves as a testament to their enduring excellence, being consistently on the list over multiple years. In doing so, they fortify leading position in the field of children’s medicine and health.



Mamiai®, intestinal health medicines for children, and Yitanjing®, cough medicines for children, have become one of the must-have home remedies for many Chinese families. Moreover, has been endeavoring to strengthen its brand impact in the field of pediatric health. Notably, Aipufen® (ibuprofen syrup), antipyretic medicine for children, Tonglang® (paracetamol syrup), antipyretic and analgesic medicine for children, Narping® (compound paracetamol syrup), cold medicine for children, and Xiandale® (levocetirizine hydrochloride syrup), allergy medicine for children, have also expanded their share of the children’s medicine market.



Furthermore, has actively pursued the research and development of new drugs. In recent years, they’ve launched groundbreaking products, including Yianping® (ambroxol hydrochloride solution for inhalation) and the first-of-its-kind single-tablet compound of amlodipine and losartan potassium in China—Meiyaping®. These innovations have ushered in a new era within the chronic disease market. It is worth noting that consistently spends the largest investments in research and development of new drugs and technologies among various pharmaceutical companies, and this investment is increasing year by year.

It is expected that will continue to promote the sustainable development of the health industry and maintain its leading position in the children’s health industry.